Genentech signs deal with Parvus to tackle inflammatory dise...

Canada’s Parvus Therapeutics has signed a deal with Roche’s Genentech unit to develop, manufacture and market drugs for inflammatory bowel disease, autoimmune liver diseases, and coeliac di